HAIC + TQB2450 + anlotinib

This is a combination therapy approach primarily being investigated for hepatocellular carcinoma (HCC). The regimen consists of: 1. **HAIC (Hepatic Arterial Infusion Chemotherapy)**: A locoregional treatment that directly administers anti-cancer drugs into liver tumors through the hepatic artery. Common chemotherapy agents used in HAIC include cisplatin (CDDP), 5-fluorouracil (5-FU), oxaliplatin, and other platinum-based drugs[1][2]. 2. **TQB2450 (benmelstobart)**: A humanized monoclonal antibody that targets PD-L1, developed by Chia Tai Tianqing Pharmaceutical Group. It functions as an immune checkpoint inhibitor[9]. 3. **Anlotinib**: A multi-target tyrosine kinase inhibitor that has anti-angiogenic properties. This combination is being investigated as adjuvant therapy for HCC patients with high risk of recurrence after resection, as indicated by an ongoing clinical trial[10]. The approach represents a strategy that combines locoregional chemotherapy with both immunotherapy and anti-angiogenic targeted therapy.